GSK Extends $2.6B Offer For Human Genome
GlaxoSmithKline PLC on Friday extended its $2.6 billion takeover offer for Human Genome Sciences Inc. through the end of June, after investors in the genetic-drug biotechnology company tendered less than 1...To view the full article, register now.
Already a subscriber? Click here to view full article